Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 11, 2016 2:44 AM ET

Capital Markets

Company Overview of Charterhouse Capital Partners LLP

Company Overview

Charterhouse Capital Partners LLP is a private equity and venture capital firm specializing in buyout investments, seed/startup, growth capital, and turnarounds. The firm prefers to invest in all sectors with a focus on industrial and commercial sectors with a focus on business service companies, financial services, leisure, support services, healthcare, telephone and telecommunications equipment, pharmaceuticals, biotechnology and life sciences, retailing, media, leisure products, outsourced business services, engineering services, chemicals, and consumer brands. It targets companies based in Europe with a focus on Western Europe, Northern Europe, and Continental Europe with a focus on Unit...

7th Floor

Warwick Court

Paternoster Square

London,  EC4M 7DX

United Kingdom

Founded in 1934

Phone:

44 20 7334 5300

Fax:

44 20 7334 5333

Key Executives for Charterhouse Capital Partners LLP

Chief Executive Officer and Executive Chairman
Finance Director
Senior Partner
Age: 51
Managing Partner
Investor Relations Director
Compensation as of Fiscal Year 2015.

Charterhouse Capital Partners LLP Key Developments

Blackstone And CVC Reportedly Shown Interest In Acquiring Doc Generici From Charterhouse

Charterhouse Capital Partners LLP has hired London-based L.E.K. Consulting to provide strategic advice ahead of a possible sale of Doc Generici s.r.l., the report said. Doc Generici, based in Milan, could be valued at between €650 million and €700 million, the report added. The Blackstone Group L.P. (NYSE:BX) and CVC Capital Partners Limited are among the buyout funds that have already shown interest in taking part in the auction.

Charterhouse Reportedly Seeks Sale Of Doc Generici

Charterhouse Capital Partners LLP has hired L.E.K. Consulting LLP to provide strategic advice to Doc Generici which could lead to a sale next year, sources familiar with the matter said. Charterhouse has tested appetite from potential suitors in recent weeks and will meet with investment banks early next year to take a final decision on the sale, which could be launched after the summer. Prospective bidders could either wait for an auction to kick off in the second half of next year or talk directly with the seller to preempt the process. The business has already drawn interest from buyout funds Blackstone (BX.N) and CVC (CVC.UL) among a series of investment firms that are looking to take part in any auction. Charterhouse declined to comment while Doc Generici and L.E.K. had no immediate comment. Blackstone and CVC declined to comment.

Investors Reportedly Seeks Acquisition Of Stakes In Armacell

Investors reportedly seeks acquisition of stakes in Armacell GmbH. Charterhouse Capital Partners LLP has set a November 18, 2015, deadline for bids for Armacell GmbH, which could be worth up to €1 billion, people familiar with its plans said. Armacell has attracted interest from other private equity groups, the sources said, with The Blackstone Group L.P. (NYSE:BX), The Carlyle Group LP (NasdaqGS:CG), CVC Capital Partners Limited, KKR & Co. L.P. (NYSE:KKR) or TowerBrook Capital Partners L.P. cited as potential bidders, as well as industrial groups, the sources said. The company could be worth up to 10 times its expected core earnings this year of roughly €100 million euros, one source said, while others said a earnings multiple of 8-9 times core earnings was a more likely valuation. After initially launching preparations for a stock market listing of Armacell last year, Charterhouse recently opted for a sales process led by Rothschild Inc.Charterhouse, Rothschild and the other private equity groups declined to comment, except for CVC, which was not immediately available for comment.

Similar Private Companies By Industry

Company Name Region
New Markets Research Ltd Europe
Ascendant Limited Europe
Pantheon Financial Limited Europe
TRIO Equity Derivatives Ltd. Europe
Mazars Financial Planning Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 30, 2015
Armacell GmbH
Merger/Acquisition
November 26, 2015
Webhelp SAS
Merger/Acquisition
October 15, 2015
Cooper, Coopération Pharmaceutique Française SAS
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Charterhouse Capital Partners LLP, please visit www.charterhouse.co.uk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.